IL301475A - Laboratory methods for increasing the vitality of the cells of the immune system - Google Patents

Laboratory methods for increasing the vitality of the cells of the immune system

Info

Publication number
IL301475A
IL301475A IL301475A IL30147523A IL301475A IL 301475 A IL301475 A IL 301475A IL 301475 A IL301475 A IL 301475A IL 30147523 A IL30147523 A IL 30147523A IL 301475 A IL301475 A IL 301475A
Authority
IL
Israel
Prior art keywords
myc
sequence
cell
agent
vaccine
Prior art date
Application number
IL301475A
Other languages
English (en)
Hebrew (he)
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Publication of IL301475A publication Critical patent/IL301475A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL301475A 2008-08-28 2009-08-28 Laboratory methods for increasing the vitality of the cells of the immune system IL301475A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9270808P 2008-08-28 2008-08-28
PCT/US2009/055443 WO2010025421A2 (en) 2008-08-28 2009-08-28 Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc

Publications (1)

Publication Number Publication Date
IL301475A true IL301475A (en) 2023-05-01

Family

ID=41722332

Family Applications (6)

Application Number Title Priority Date Filing Date
IL301475A IL301475A (en) 2008-08-28 2009-08-28 Laboratory methods for increasing the vitality of the cells of the immune system
IL209968A IL209968A (en) 2008-08-28 2010-12-13 Immune system-modulating composition comprising a transporter peptide sequence-myc fusion protein
IL232432A IL232432A (en) 2008-08-28 2014-05-04 Modulators of myc and uses thereof in modulating the viability of immune cells
IL249700A IL249700B (en) 2008-08-28 2016-12-21 In vitro methods for increasing viability of immune-cells
IL264254A IL264254B (en) 2008-08-28 2019-01-15 In vitro methods for increasing viability of immune-cells
IL276146A IL276146B2 (en) 2008-08-28 2020-07-19 Laboratory methods for increasing the vitality of the cells of the immune system

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL209968A IL209968A (en) 2008-08-28 2010-12-13 Immune system-modulating composition comprising a transporter peptide sequence-myc fusion protein
IL232432A IL232432A (en) 2008-08-28 2014-05-04 Modulators of myc and uses thereof in modulating the viability of immune cells
IL249700A IL249700B (en) 2008-08-28 2016-12-21 In vitro methods for increasing viability of immune-cells
IL264254A IL264254B (en) 2008-08-28 2019-01-15 In vitro methods for increasing viability of immune-cells
IL276146A IL276146B2 (en) 2008-08-28 2020-07-19 Laboratory methods for increasing the vitality of the cells of the immune system

Country Status (11)

Country Link
US (6) US8784825B2 (enExample)
EP (4) EP2318435B1 (enExample)
JP (5) JP5812861B2 (enExample)
CN (2) CN102089323B (enExample)
AU (1) AU2009285547B2 (enExample)
CA (1) CA2735522C (enExample)
DK (3) DK3339321T3 (enExample)
ES (3) ES2681478T3 (enExample)
IL (6) IL301475A (enExample)
SG (1) SG193831A1 (enExample)
WO (1) WO2010025421A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
JP2010521170A (ja) * 2007-03-13 2010-06-24 ナショナル ジューイッシュ ヘルス 抗体の生成方法
KR101803099B1 (ko) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
EP2877189B1 (en) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
CN106795488B (zh) 2014-09-16 2021-03-30 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
EP4242298A2 (en) * 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) * 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
SG11202000612TA (en) * 2017-08-03 2020-02-27 Taiga Biotechnologies Inc Methods and compositions for the treatment of melanoma
CN111094328A (zh) * 2017-08-03 2020-05-01 泰加生物工艺学公司 用于治疗癌症的方法和组合物
AU2020272664A1 (en) * 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) * 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
JP7197538B2 (ja) * 2020-07-03 2022-12-27 タイガ バイオテクノロジーズ，インク． メラノーマの処置のための方法および組成物
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS62501537A (ja) 1984-12-21 1987-06-25 テクニクロン・リサ−チ・パ−トナ−ズ・ワン リンパ球細胞を電気的に不滅化するための方法
DE3531430A1 (de) 1985-09-03 1987-03-05 Biotest Pharma Gmbh Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4900322A (en) 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5476996A (en) * 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5849288A (en) * 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
AU781922B2 (en) 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5289858A (en) 1991-12-18 1994-03-01 Abbott Laboratories System for accommodating withdrawal of liquid from a bulk supply
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
US5580760A (en) * 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
US5824837A (en) * 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
WO1995023512A1 (en) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP0893493A3 (de) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
EP1070757B1 (en) 1998-04-08 2005-02-02 Shionogi & Co., Ltd. Methods for isolating osteoclast precursor cells and inducing the differentiation of the same into osteoclasts
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) * 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
CA2364690A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
AU4070500A (en) 1999-04-05 2000-10-23 Biocrystal Limited Assay kits and methods for immune complex-mediated activation involving shed antigens
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
ATE342275T1 (de) 1999-04-12 2006-11-15 Heart Biosystems Gmbh Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
CA2390011A1 (en) 1999-11-10 2001-05-17 Rigel Pharmaceuticals, Inc. Methods and compositions comprising renilla gfp
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) * 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
WO2001087058A1 (en) * 2000-05-15 2001-11-22 Sonoko Habu Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) * 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
CA2423093C (en) 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
WO2002036738A2 (en) 2000-10-30 2002-05-10 Kalobios, Inc. Affinity maturation by competitive selection
ES2386884T3 (es) 2000-11-01 2012-09-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos
US7145055B2 (en) * 2000-12-01 2006-12-05 Central Institute For Experimental Animals Method of producing a mouse suitable for the engraftment, differentiation and proliferation of heterologous cells, mouse produced by this method and use of the mouse
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
JP3454818B1 (ja) 2001-03-16 2003-10-06 直哉 小林 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途
JP4317940B2 (ja) 2001-08-31 2009-08-19 イミュノコア・リミテッド 物質
CN100506978C (zh) 2001-09-21 2009-07-01 中国人民解放军军事医学科学院野战输血研究所 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
JP2005508171A (ja) 2001-11-02 2005-03-31 タノックス インコーポレーテッド Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2003068941A2 (en) 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US7211191B2 (en) 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
JP2005523012A (ja) 2002-04-16 2005-08-04 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌モデル
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
CN1659187A (zh) 2002-05-10 2005-08-24 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
DK1506223T3 (da) 2002-05-16 2006-04-10 Bavarian Nordic As Fusionsprotein af regulatoriske/accessoriske HIV-proteiner
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
PT1408114E (pt) * 2002-10-11 2007-04-30 Imvision Gmbh Moléculas modulares de transportes de antigénios ( moléculas mat ) para modulação de respostas imunitárias, correspondentes construções, processos e utilizações.
US20060154331A1 (en) * 2002-10-15 2006-07-13 Nili Avidan Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
WO2004050885A2 (en) 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
ATE371437T1 (de) 2003-02-17 2007-09-15 Peter Burkhard Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7482016B2 (en) 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
DK1623017T3 (da) 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
WO2005014785A2 (en) 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
AU2004316996A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL161903A0 (en) 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
CA2546794C (en) 2003-11-19 2013-09-17 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US7705049B2 (en) * 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
JP2005232148A (ja) 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
WO2005114215A2 (en) 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
DE602005011617D1 (de) 2004-05-19 2009-01-22 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
US20060068469A1 (en) 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
US7767453B2 (en) * 2004-10-20 2010-08-03 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
US8795650B2 (en) 2004-12-09 2014-08-05 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) * 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
EP1876894A1 (en) 2005-04-26 2008-01-16 The Board of Trustees of the University of Illinois Nucleoside compounds and methods of use thereof
EP1885754B1 (en) 2005-05-25 2011-02-09 Immunocore Ltd. T cell receptors which specifically bind to vygfvracl-hla-a24
EP1928484B1 (en) * 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US20070047583A1 (en) 2005-08-29 2007-03-01 Siemens Aktiengesellschaft Method for using a short address in a packet header
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
CA2626584A1 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
US20080070256A1 (en) 2006-07-26 2008-03-20 National Jewish Medical And Research Center Non-Human Animal Models for B-cell Non-Hodgkin's Lymphoma and Uses Thereof
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
JP2010521170A (ja) 2007-03-13 2010-06-24 ナショナル ジューイッシュ ヘルス 抗体の生成方法
WO2009059304A2 (en) 2007-11-02 2009-05-07 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
ES2690554T3 (es) 2008-03-17 2018-11-21 The Scripps Research Institute Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
KR101803099B1 (ko) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
US8481492B2 (en) 2008-06-13 2013-07-09 Life & Brain Gmbh Fusion protein and use thereof
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20120107317A1 (en) 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
CA2849378A1 (en) 2011-09-21 2013-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems for sirna
RU2665548C2 (ru) 2012-05-03 2018-08-30 Фред Хатчинсон Кансэр Рисёч Сентер Способ получения клеток, экспрессирующих т-клеточный рецептор
EP2852381B1 (en) 2012-05-23 2020-10-07 The Ohio State University Lipid nanoparticle compositions and methods of making and methods of using the same
DE102012209673A1 (de) 2012-06-08 2013-12-24 Artcline Gmbh Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation
EP2877189B1 (en) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US20140109246A1 (en) 2012-09-24 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP2961416B1 (en) 2013-03-01 2019-11-13 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
US20160010058A1 (en) 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
IL286025B2 (en) 2014-12-24 2023-11-01 Neximmune Inc Nanoparticle preparations and immunotherapy methods
KR20180081507A (ko) 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. 브로모도메인 저해제와 관문 차단의 조합 요법
US10712344B2 (en) 2016-01-15 2020-07-14 Berkeley Lights, Inc. Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
US20200054660A1 (en) 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Also Published As

Publication number Publication date
IL249700B (en) 2019-02-28
IL232432A0 (en) 2014-06-30
US9775897B2 (en) 2017-10-03
CN102089323A (zh) 2011-06-08
IL209968A (en) 2014-11-30
CN104353066A (zh) 2015-02-18
JP5812861B2 (ja) 2015-11-17
JP6167130B2 (ja) 2017-07-19
JP6817353B2 (ja) 2021-01-20
DK2966084T3 (en) 2018-08-06
IL276146A (en) 2020-09-30
JP6484293B2 (ja) 2019-03-13
JP2017197567A (ja) 2017-11-02
JP2019116481A (ja) 2019-07-18
JP2015147789A (ja) 2015-08-20
ES2879225T3 (es) 2021-11-22
US20180092972A1 (en) 2018-04-05
US20100055129A1 (en) 2010-03-04
IL232432A (en) 2017-01-31
SG193831A1 (en) 2013-10-30
DK2318435T3 (en) 2016-02-29
IL264254B (en) 2020-08-31
US20240156957A1 (en) 2024-05-16
EP3916010A1 (en) 2021-12-01
US10556006B2 (en) 2020-02-11
US20220362377A1 (en) 2022-11-17
AU2009285547A1 (en) 2010-03-04
ES2681478T3 (es) 2018-09-13
US8784825B2 (en) 2014-07-22
US20200215188A1 (en) 2020-07-09
EP2318435B1 (en) 2015-12-23
US11369678B2 (en) 2022-06-28
EP2966084B1 (en) 2018-04-25
EP2318435A2 (en) 2011-05-11
HK1159643A1 (zh) 2012-08-03
HK1219491A1 (en) 2017-04-07
IL276146B2 (en) 2023-08-01
CA2735522A1 (en) 2010-03-04
US20130177586A1 (en) 2013-07-11
JP7208965B2 (ja) 2023-01-19
JP2021073184A (ja) 2021-05-13
EP2966084A1 (en) 2016-01-13
JP2012501347A (ja) 2012-01-19
IL249700A0 (en) 2017-02-28
IL264254A (en) 2019-02-28
WO2010025421A2 (en) 2010-03-04
WO2010025421A3 (en) 2010-08-19
EP3339321A1 (en) 2018-06-27
EP3339321B1 (en) 2021-04-28
US20140356392A1 (en) 2014-12-04
US8828723B2 (en) 2014-09-09
IL276146B1 (en) 2023-04-01
CN104353066B (zh) 2017-05-10
CN102089323B (zh) 2015-01-21
AU2009285547B2 (en) 2012-05-31
HK1257269A1 (en) 2019-10-18
CA2735522C (en) 2017-04-18
DK3339321T3 (da) 2021-06-21
ES2561599T3 (es) 2016-02-29
IL209968A0 (en) 2011-02-28
EP2318435A4 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
US11369678B2 (en) Compositions and methods for modulating immune cells
US12496341B2 (en) Methods for reducing anergy in lymphocytes using modulators of MYC
AU2012216462B2 (en) Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
HK40054473A (en) Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
AU2015205879A1 (en) Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
HK1257269B (en) Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
HK1219491B (en) Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
HK1159643B (en) Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc